In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants
J. G. Thoene, R. F. Gavin, A. Towne, L. Wattay, M. G. Ferrari, R. Pal
This study shows cysteamine HCl inhibits multiple SARS-CoV-2 variants in vitro, suggesting potential as a topical nasal treatment to mitigate infection and transmission.
bioRxiv · Oct 2, 2021Microbiology